Diabetes Complications Clinical Trial
Official title:
Benefits of Insoles With Real-Time Alert and Foot Self-Care Education in Improving Adherence for Prescribed Footwear in Patients With Diabetes Mellitus
Novel approaches to promote adherence to diabetic footwear and prevent high incidence of diabetes foot ulcers are urgently needed. Investigators propose to translate an innovative and practical technology to supplement clinical and risk evaluation for patients with diabetes through wearable insoles and smart watch, along with foot self-care education, to improve adherence to prescribed footwear and reduce incidence of foot ulcers in those with diabetes and at risk for foot ulcers.
Uncontrolled diabetes is the cause of diabetes-related limb amputations. Diabetes-related amputations are huge problems, expensive to manage, and affect the quality of life. Diabetes foot ulcers (DFU) are foot-related injuries to the foot that are a direct result of neuropathy and peripheral artery diseases and have been identified as major risk factors for amputations. To prevent DFU, diabetes footwear is recommended, however, adherence is poor. Patients are not routinely adherent to the recommended diabetic footwear. In addition, current diabetic footwear is not effective in preventing most initial and recurrent DFUs. Although the causal mechanisms for DFU are multi-factorial, evidence exists that elevated plantar pressure contributes to the development of DFU, which is currently managed by devices ineffective in reducing pressure in certain areas of the foot. Foot care education by clinicians regarding adherence to prescribed footwear is not effective in reducing the initial and recurrent DFUs. A recent study by Najafi and colleagues demonstrated the efficacy and feasibility of smart insoles with real-time alerts for plantar pressure offloading, which causes more than 50% of pressure ulcers in at-risk individuals with diabetes. The device was designed to cue offloading to manage unprotected sustained plantar pressures to prevent foot ulceration. Interestingly, their study suggested that in the group with at least 1 alert every 2 hours, adherence to prescribed footwear was increased or retained over time; whereas a lower number of alerts reduced adherence. Authors speculated that reduced adherence in the low-alert group may be linked to disengagement or reduced perception of benefit. It is unknown whether smart insoles with alerts will improve the use of footwear and lower the incidence of DFU, compared to usual care and the role of self-efficacy in mediating among performance, desired behavior, and desired outcomes (increase adherence to diabetic footwear and decrease the incidence of foot ulcer) among participants in the proposed study. To fill the gaps, investigators aim to examine whether integration of a diabetes foot self-care education and smart insoles with alerts may sustain adherence, irrespective of several daily alerts, to prescribed footwear, compared to usual care in those at risk for DFU. In this study (R21) phase, investigators are proposing a randomized controlled trial to evaluate the efficacy of insoles with real-time alert and foot self-care education in improving adherence to prescribed footwear in diabetes patients at risk for DFU. In Aim 1, investigators will examine whether smart insoles with real-time alert components plus foot self-care education compared to the smart insole with alerts alone and usual care will improve adherence to prescribed footwear in high-risk individuals for DFU (history of neuropathy and peripheral artery disease [PAD]). In Aim 2, investigators will examine trends across groups in the incidence of initial and recurrent DFU. The overall goal is to generate data for an R01 submission to evaluate the effectiveness of combined smart insoles with real-time alert plus foot self-care education in preventing the incidence of initial and recurrent DFU in those at-risk individuals with diabetes. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03022721 -
Heidelberg Study on Diabetes and Complications
|
N/A | |
Withdrawn |
NCT02580266 -
Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes
|
||
Completed |
NCT02423434 -
Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
|
||
Completed |
NCT03426566 -
Abnormal Plantar Pressure in Patients With Diabetes
|
||
Completed |
NCT01695278 -
A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community
|
Phase 3 | |
Completed |
NCT02588898 -
B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes
|
||
Completed |
NCT00815178 -
Effects of Inspiratory Muscle Training on Type 2 Diabetes Mellitus Patients With Inspiratory Muscle Weakness
|
N/A | |
Not yet recruiting |
NCT04537676 -
Patient Empowerment Study
|
||
Terminated |
NCT02915263 -
The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes
|
Phase 2 | |
Completed |
NCT01929018 -
Collaborative-care Rehabilitation After Dysvascular Amputation
|
N/A | |
Completed |
NCT03877523 -
Cocarnit Effects on Macrophages Polarization
|
N/A | |
Completed |
NCT02947828 -
Polyneuropathy in Diabetes Mellitus Type 2
|
||
Completed |
NCT02928939 -
Therapeutic Conflicts and Multimorbidity
|
||
Recruiting |
NCT02275091 -
Children With Diabetes at Risk for Heart Disease.
|
||
Terminated |
NCT00529204 -
Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT04963998 -
Safety and Efficacy Study of MedCu Wound Dressings
|
N/A | |
Recruiting |
NCT06321029 -
Electronic Diabetes Tune-Up Group (eDTU) for African Americans
|
N/A | |
Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT05231642 -
Individualised Postprandial Glucose Responses in Type 1 Diabetes
|
N/A | |
Completed |
NCT03392441 -
Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes
|
N/A |